金种子酒(600199) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥139,209,255.95, a decrease of 54.41% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was -¥110,624,063.74, representing a decline of 3,843.21% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥114,913,634.87, with no applicable year-on-year comparison[2] - The basic earnings per share for Q3 2024 was -¥0.1682, reflecting a year-on-year decline of 3,832.89%[4] - The diluted earnings per share for Q3 2024 was also -¥0.1682, with a similar year-on-year decline[4] - Total operating revenue for the first three quarters of 2024 was CNY 805,894,813.48, a decrease of 25% compared to CNY 1,073,051,897.04 in the same period of 2023[19] - Operating profit for the first three quarters of 2024 was a loss of CNY 100,706,472.72, compared to a loss of CNY 35,198,743.69 in the same period of 2023[19] - Net profit for the first three quarters of 2024 showed a total loss of CNY 93,639,058.57, worsening from a loss of CNY 26,444,276.14 in 2023[19] - The net profit for the third quarter of 2024 was -98,747,874.34 RMB, compared to -32,994,207.03 RMB in the same period of 2023, indicating a significant decline in profitability[20] - The total comprehensive income attributable to the parent company for the third quarter of 2024 was -99,526,070.30 RMB, compared to -34,859,358.56 RMB in the same quarter of 2023[20] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was -¥256,178,535.96, a decrease of 322.89% compared to the same period last year[2] - Total cash inflow from operating activities for the first nine months of 2024 was 829,710,423.26 RMB, down from 1,304,144,783.70 RMB in the first nine months of 2023, reflecting a decrease of approximately 36.4%[21] - The net cash flow from operating activities for the first nine months of 2024 was -256,178,535.96 RMB, contrasting with a positive cash flow of 114,937,194.04 RMB in the same period of 2023[21] - Cash and cash equivalents at the end of the third quarter of 2024 amounted to 318,826,307.49 RMB, down from 511,375,811.79 RMB at the end of the same period in 2023, representing a decrease of approximately 37.7%[22] - The company recorded a net cash flow from investing activities of -8,292,338.73 RMB for the first nine months of 2024, compared to -62,186,470.64 RMB in the same period of 2023, showing an improvement in cash flow management[22] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥3,307,254,981.26, a decrease of 4.86% from the end of the previous year[4] - The equity attributable to shareholders at the end of Q3 2024 was ¥2,417,409,434.38, down 4.04% from the end of the previous year[4] - Total assets as of the end of the reporting period were CNY 3,307,254,981.26, down from CNY 3,476,257,231.71 at the end of the previous period[17] - Total liabilities decreased to CNY 876,978,893.61 from CNY 945,036,906.27, indicating a reduction of about 7%[17] - The total equity attributable to shareholders was CNY 2,417,409,434.38, down from CNY 2,519,131,868.12, reflecting a decrease of approximately 4%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 125,051 shares[10] - The largest shareholder, Anhui Jinzhongzi Group Co., Ltd., holds 178,257,084 shares, accounting for 27.10% of total shares[10] - The total number of shares held by the top ten shareholders includes significant stakes from various investment funds, with China Bank holding 32,550,443 shares, representing 4.95%[10] - There were no changes in the relationships or concerted actions among the top shareholders[12] Operational Changes - The company reported a significant decrease in revenue due to the cessation of pharmaceutical sales operations, which impacted overall income[7] - The company recognized government subsidies amounting to ¥2,410,234.75 during the reporting period, contributing to non-recurring gains[5] - The company has not reported any new strategies or mergers during this quarter[14] - The company is focusing on cost control and efficiency improvements to navigate the challenging market environment[19] Research and Development - Research and development expenses increased to CNY 17,116,644.63 in 2024, up from CNY 11,014,556.73 in 2023, marking a rise of approximately 55%[19] Other Financial Metrics - The company's cash and cash equivalents decreased to approximately RMB 353.45 million from RMB 507.31 million at the end of 2023[15] - Accounts receivable dropped to RMB 69.50 million from RMB 147.37 million year-over-year[15] - Inventory increased to RMB 1.51 billion from RMB 1.47 billion at the end of 2023, indicating a growth of approximately 2.5%[15] - The total current assets decreased to approximately RMB 1.99 billion from RMB 2.19 billion[15] - The company reported a significant increase in prepayments, which decreased to RMB 9.26 million from RMB 31.70 million[15] - The cash outflow for purchasing fixed assets and other long-term assets in the first nine months of 2024 was 54,818,846.64 RMB, compared to 62,213,470.64 RMB in the same period of 2023, indicating a decrease of approximately 11.2%[22] - Total cash inflow from financing activities for the first nine months of 2024 was 199,162,955.43 RMB, while cash outflow was 84,976,642.97 RMB, resulting in a net cash flow of 114,186,312.46 RMB[22] Accounting Standards - The company has not applied new accounting standards or interpretations that would affect the financial statements for the year of first implementation[23]